delaminomycins.
Delaminomycins were isolated from the mycelium and cultured broth of Streptomyces albulus MJ202-72F3. It was purified by use of centrifugal partition chromatography (CPC), preparative reverse phase HPLCand Sephadex LH-20 and was obtained as a white powder. Delaminomycins with inhibitory activity for cell adhesion to ECMcomponents suppressed immune responses in vitro and in vivo and exhibited antimicrobial activity on Gram-positive bacteria.
It is known that most host-mediated responses involve immune responses, and metastases or invasion of tumors results from cell-cell interactions amongvarious kinds of cells which interact with ECMreceptors. In order to develop a newclass of immunomodulator or an inhibitor of tumor metastases, we have sought a low molecular weight inhibitor of cell adhesion in microbial products to components of the ECMand found a novel antibiotic, named delaminomycin, in cultured mycelium of Streptomyces albulus MJ202-72F3. Delaminomycinsare non-peptide1~3) and inhibit the adhesion of tumor cells to components of the ECM.In this paper, we report the taxonomy, fermentation, isolation and biological activity of delaminomycins A, B and C.
Cell Adhesion Assay Weemployed Con A-activated EL4 cells adhesion assay for screening of ECMantagonists in cultured broth of microorganisms and for assessment of the activity of each fraction during purification of delaminomycins. The inhibitory activity of EL4 cells adhesion assay was determined as follows. Con A-activated EL4 cell adhesion assay: Cell adhesion assays were performed by the partially modified methods reported by Graf et al.4'5\ Shimizu et al.6 ) and Hershkoviz et aln). EL4 cells were maintained in RPMI-1640 mediumsupplemented with 10% fetal calf serum (FCS). After cells were grown in culture bottles up to 80%confluence, they were washed with RPMImediumand resuspended in RPMImedium containing 1% FCS, 10/ig/ml of Con A and 10mMHEPES. FN (porcine plasma, Iwaki Glass) or LM (mouse EHS sarcoma, Iwaki Glass) were added to the wells: 0.5fig of FN or 1.25/ig of LMin 50fA of PBSper well for 17 hours at 10°C. Protein-coated microwells were rinsed twice with PBSand blocked for 30minutes with 1% bovine serum albumin (BSA) in PBS. 10fi\ of cultured broth or test samples and 105 cells in 100/xl of the medium were added onto the protein-coated microwells and incubated for 1 hour at 37°C in 5%CO2, 95% air. After incubation, plates were gently washed three times with warmed PBS (37°C) to remove non-adherent cells. Adherent cells were fixed with 20 /xl of glutaraldehyde (GA) per well for 30 minutes at room temperature, then washed with tap water and dried in oven for 10 minutes at 60°C to remove GA. The fixed cells were stained with 100/il of 0.4% crystal violet in 20% aqueous MeOHper well for 10 minutes at room temperature, then washed with tap water three times and dried. To extract the dye, 100[A of lmMHC1 in 30% aqueous EtOH was added into each well. The A54r0 of individual wells was measured using a microtiter plate reader (Titertek Multiskan). Each assay was performed in duplicates.
Taxonomy
The producing microorganism, strain MJ202-72F3, was isolated from a soil sample collected in Ohtsuki-shi, Yamanashi Prefecture, Japan. The cultural characteristics of strain MJ202-72F3 are shown in Table 1 . Strain MJ202-72F3 has a branched vegetative hyphae and the end of aerial hyphae in the form of spiral. Mature spore chains were moderately long, with 10 to 50 or more spores per chain. Spore surface wasspiny or warty. Nosporangia, motile spores or synnematawere observed. Vegetative masscolor was colorless to pale yellow on the various media and aerial mass color was in the gray color series on sucrose -nitrate agar and yeast extract-malt extract agar as described in Table 1 . No pigment was found in the mediumin sucrose -nitrate agar, yeast extract -malt extract agar, oatmeal agar, inorganic salts -starch agar, or glycerol -asparagine agar.
Physiological characteristics of strain MJ202-72F3 are shown in Table 2 . The whole cell hydrolysate contained ix-type of diaminopimelic acid. Melanoid pigments were not formed in peptone -yeast extract -iron agar, tyrosine agar, or tryptone -yeast extract broth.
Accordingly, strain MJ202-72F3 is considered to be in the genus Streptomyces. Among Streptomyces, Streptomyces albulus8'9) and Streptomyces natalensis10) are similar to strain MJ202-72F3. Strain MJ202-72F3 is a little different from both S. albulus and S. natalensis in liquefaction of gelatin, coagulation of milk, peptonization of milk and hydrolysis of starch. However, these characteristics are thought to easily change under the environmental conditions. Strain MJ202-72F3 is closely related to S. albulus in aerial The color names used in this table were based on the Color Standard (Nihon Sikisai Co., Ltd.) and Color
HarmonyManual (Container Corporation of America). mass color and utilization of carbon sources. Therefore, it was designated as S. albulus MJ202-72F3. The strain was deposited in the Fermentation Research Institute, Agency of Industrial Science and Technology, Japan, with the accession No. FERMP-12674. Fermentation The strain MJ202-72F3on an agar slant was inoculated into a 500-ml Erlenmeyer flask containing 110ml of a seed medium and cultured at 30°C for 3 days on a rotary shaker (180rpm). The seed medium consisted of glucose 1.5%, yeast extract (Nippon-Seiyaku) 0.25%, casamino acids (Difco) 0.25%, CaCO3 0.4% and pH of the medium was not adjusted. Two ml of this seed culture was inoculated into 110ml of a production medium in 500-ml Erlenmeyer flask and cultured at 28°C for 6 days on a rotary shaker (180rpm) for production. The production medium was consisted of glucose 3.0%, yeast extract 0.5%, casamino acids 0.5%, NaNO3 0.2%, KC1 0.2%, CaCO3 0.4% and pH of the medium was not adjusted. A typical fermentation profile for production of delaminomycin A in cultured mycelium is shown in Fig. 1 . The activity of delaminomycins was assessed by the inhibitory activity of 10/il of broth and MeOH extract of mycelium against Con A-activated EL4 cells adhesion assay. The amounts of delaminomycins were determined by HPLC using a CAPCELLPAK C18 column (Shiseido) with a mobile phase of MeOH-CH3CN-2-PrOH -25 mMNH4OAc(30 : 30 : 5 : 35) at 35°C. Although delaminomycins were found in both cultured broth and mycelium, the active principle was in the mycelium (data not shown).
Delaminomycin A was obtained as the main component in delaminomycins, and the production ratio of delaminomycins A, B and C was approximately 100 : 10 : 5. After 6 days cultivation, delaminomycin A accumulated in mycelium up to 180 /ig/ml.
Isolation and Purification
The procedure for isolation purification of delaminomycins is shown in Fig. 2 . The activity of delaminomycins was assessed Con A-activated EL4cells adhesion assay. Each fraction in the process of isolation was diluted with MeOHand assessed. The cultured broth (10 liters) was centrifuged and the mycelium was harvested. The mycelium was extracted twice with five volumesof MeOH per wet weight of mycelium.The extract was concentrated under reduced pressure to give an aqueous solution. The aqueous solution was extracted twice with n-BuOH and the organic layer was evaporated under reduced pressure. The crude material (3 g) was subjected to centrifugal partition chromatography (CPC, Sanki Engineering) previously equilibrated with the lower layer of CHC13-MeOH-water (2: 2 : 1) at 25°C, 400rpm. Delaminomycin A was eluted with the mobile phase of the upper layer of CHC13-MeOH-water (2 : 2 : 1) in the ascending mode and evaporated under reduced pressure. Delaminomycins B and C remained in the immobile phase in the ascending mode, and were eluted with the lower layer of CHC13-MeOH-water (2 : 2 : 1) in descending mode and evaporated under reduced pressure. The residue containing delaminomycin A was applied to a reverse phase HPLC column (CAPCELLPAK C18 20x250mm, flow rate 5ml/minute) and eluted with a gradient of MeOH-25mM NH4OAc-CH3CN(10 : 60 : 30-60 : 10 : 30 linear gradient in 90 minutes). The active fractions containing delaminomycin A were concentrated under reduced pressure and then loaded onto a Sephadex Lp-20 column. The activity was eluted with MeOHand concentrated under reduced pressure to give pure delaminomycin A as a colorless powder (320 mg). The fraction containing delaminomycins B and C was injected to CPC previously equilibrated with the lower layer of «-hexane-EtOAc-CH3CN (7 : 2 : 3) at 25°C, 900 rpm. Delaminomycin B and C fractions remaining in the immobile phase in ascending mode, were eluted with the lower layer of rc-hexane -EtOAc-CH3CN(7 : 2 : 3) in the descending mode, and were concentrated under reduced pressure. The resulting residue was applied to a reverse phase HPLCC18-column and eluted by the same gradient system as described above. Active fractions B and C were collected and concentrated under reduced pressure, and then loaded onto a Sephadex LH-20 column and eluted with MeOH. Then each active fraction was concentrated to dryness and 30mgof delaminomycin B and 13 mg of delaminomycin C were obtained as a colorless powder.
Biological Activity Con A-activated EL4 Cell Adhesion Assay Various amounts of delaminomycins and 105 cells in 100/zl of assay mediumwere added onto the protein-coated microwells and incubated for 1 hour at 37°C in 5% CO2, 95% air. Each assay was performed in triplicate. The viability of EL4 cells treated with test samples for 60 minutes was checked by the trypan blue dye exclusion test. As shown in Table 3 , all delaminomycins inhibited Con A-activated adhesion of EL4 cells to each ECMcomponent at 4.8 to 13.7/xg/ml.
B16 Cell Adhesion Assay
B16 melanomacell adhesion assays were performed using the modified method reported by Graf et a/.4)5). Briefly, B16 cells were maintained in Dulbecco's modified Eagle's medium(DMEM) supplemented with 10%FCS. The cells grown up to 80% confluence in culture bottles were detached with a solution of 2mMEDTA,after washing, resuspended in serum-free DMEM containing 0.1% BSA, 25 /ig/ml of cycloheximide and 20 mMHEPES. Delaminomycins at different concentrations and B16 cells (105 in 100/il) were added to the ECMprotein-coated wells including CL. The plate was incubated for 1 hour at 37°C in 95%air and 5% CO2and adhesion assays were performed in triplicate as described above. As shown in Table 4 , delaminomycins A and B inhibited adhesion of B16 melanoma cells to FN, LMand CL, although C showed no inhibition on FN at 100jjg/ml. Delaminomycin A showed stronger inhibitory activity than B and C.
Mixed Lymphocytes Culture Reaction (MLCR)
MLCRassays were performed by the method described previously1 1}. Spleen cells (nylon wool-passed) MeOHwere diluted with RPMI-1640 and added to cultures. Triplicate determinations were made. As shown in Table 5 , delaminomycins A, B and C inhibited MLCR in a dose dependent manner and the IC50 values were 8.6jug/ml, l.l^g/ml and 0.5 //g/ml, respectively.
Delaminomycin A was dissolved in DMSO -Tween 80-saline (9: 1 :90) and given ip dialy from days 0 to 4 after immunization. Vehicle (0.25ml) was given ip as same schedule for drug. P<0.001 (*) as compared with vehicle group.
Effect of Delaminomycin A on Immune Responses to Sheep Red Blood Cells (SRBC) in Mice
The effect of delaminomycinA on immuneresponses to SRBCin mice was investigated as follows. Antibody formation: Female CDFXmice (10 weeks old) were immunized on day 0 with 1 x 108 SRBC iv. Antibody formation was determined on day 4 by enumerating plaque forming cells (PFC) according to the method described previously12). Drug was administrated ip daily from days 1 to 3 after immunization. Delaminomycin A in doses of 0.2 to 50mg/kg did not suppress antibody formation. after the elicitation, footpad thickness was measured with a caliper13). Drug was injected ip daily for 5 day%s starting from the day of immunization. As shown in Fig. 3 , delaminomycin A at doses of 3.13 to 50 mg/kg strongly suppressed the DTHresponse. Cytotoxicity The cytotoxicity of delaminomycins on tumor cells is shown in Table 6 . Tumorcells were cultured in RPMI-1640 containing 10% FCS with test samples for 72 hours and cytotoxicity was determined by MTTassay. Among delaminomycins, C showed the strongest cytotoxic activity at concentration of lower than 10 /xg/ml on the tumor cells tested except for L1210. L1210 cells were more resistant to delaminomycins than other tumorcells.
Antimicrobial Activity Antimicrobial activity of delaminomycins was examined by the serial agar dilution method using Mueller Hinton agar (Difco) for antibacterial tests >  >100  >100  >  >100  >100  >  >100  >100  >  >100  >100  >  >100  >100  >  >100  >100  >  >100  >100  >  >100  >100  >  >100  >100  >  >100  >100  >  >100  >100  >  >100  >100  >  >100  >100  >   10  10  10  10  10  10  10  10  10  10  10  10  10 T. mentagrophytes F-l5 (833) Aspergillus nigar F-l6
A. fumigatus F-181 Pseudomonas fluorescens >100 >100 >100 >100 >50 >50 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >50 100 100 100 >ioo >100 >100 >100 >100 >100 >100 >100 >100 >100 inhibitory concentration (MIC) value is expressed as the minimumconcentration which inhibits growth of the microorganisms. As shown in Table 7 , delaminomycins A, B and C showed antibacterial activity only against Gram-positive bacteria but not against fungi.
Toxicity
The LD50 value of delaminomycin A was found to be more than 500mg/kg ip to ICR mice.
Discussion
In order to develop a new class of immunomodulatorsand an inhibitor of tumor metastases from microbial products, we have sought ECMreceptor antagonists from cultured broths of 3,600 strains and found a low molecular weight inhibitor, nameddelaminomycins.
WhenEL4 cells were activated by Con A, they showed the same ability to adhere to LMand FN as that of T cells. Adhesion of T cells to ECMcomponents requires stimulation of T cells by antigen or mitogen6'7). Since adhesion of non-activated EL4cells to ECMprotein coated wells was not observed (data not shown), we employed Con A-activated EL4 cells instead of T cells for assay. As shown in Table  3 , delaminomycins inhibited adhesion of Con A-activated EL4 cells to ECMcomponents. In this assay, however, it was not excluded whether the effect might be due to inhibition of the binding of Con A to EL4 cells and/or of signal transduction induced by Con A. To elucidate this possibility, we tested cell adhesion assay using B16 melanoma cells instead of EL4 cells because B16 cells have an active receptor for FN, LMand CL4>5'14>15). Results shown in Table 4 indicate that delaminomycins inhibited adhesion of B16 melanomacells to the ECMcomponents to the same degree as EL4 cells. Thus, it can be concluded that delaminomycins are neither inhibitors of Con A binding to EL4 cells nor inhibitors of signal transduction induced by Con A, but rather are inhibitors of cell adhesion to ECMcomponents.
To determine the effect of delaminomycins against immunesystems in vivo and in vitro, we investigated effects of delaminomycins on MLCRin vitro and delaminomycin A on antibody formation and DTHin vivo. Results suggest that delaminomycins suppressed T cell-mediated immune responses although delaminomycin A did not inhibit antibody formation to a T-dependent antigen, SRBCin mice. Thus, it can be considered that delaminomycin A may inhibit generation of effector T cells or may block the effector-target interaction. Therefore, weconcluded that delaminomycins, novel antagonists for ECM receptors, are a newclass of immunomodulator. The physico-chemical properties and structural elucidation of the delaminomycin A will be reported1 6).
